The popular once-weekly Tirzepatide injection — widely used overseas for weight loss and developed by Eli Lily — is now available at our clinic.
Interested in the once- weekly weight loss injection? Enquire Now! to WhatsApp us and speak with our team directly.
CagriSema is an emerging injectable medication currently under clinical evaluation for medical weight management. At present, it has not been commercially launched for routine clinical use in Singapore.
The information on this page is provided for educational purposes to help patients understand how newer combination weight loss therapies may work, their safety considerations, and the importance of doctor supervision should such treatments become clinically available.
While CagriSema is not yet available locally, several established prescription-based medical weight loss treatments are already offered in Singapore under medical supervision, including Wegovy, Ozempic, Mounjaro, and Rybelsus.
CagriSema is an investigational combination injectable medication currently under clinical evaluation for medical weight management. It is designed as a once-weekly subcutaneous injection that combines a glucagon-like peptide-1 (GLP-1) receptor agonist with a long-acting amylin analogue. This dual-component formulation targets complementary hormonal pathways involved in appetite regulation, satiety, and energy balance.
By addressing more than one mechanism related to hunger control, CagriSema represents a broader therapeutic approach compared with traditional single-agent weight loss injections. Its combination design has generated clinical interest for individuals who may require more comprehensive appetite regulation under medical supervision.
As a prescription-based treatment, CagriSema is intended to be used only within a structured, doctor-guided weight management programme. It is not a substitute for medical assessment or long-term weight management strategies, but rather a potential adjunct under appropriate clinical supervision. Suitability, safety, and effectiveness vary between individuals and require careful medical evaluation.
CagriSema works through a combination of two complementary active components: cagrilintide and semaglutide. Together, these agents target distinct but interconnected hormonal pathways involved in appetite regulation, satiety, and energy balance, providing a broader approach to medical weight management than single-agent therapies.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that influences appetite regulation by slowing gastric emptying, enhancing satiety, and reducing hunger signals. Cagrilintide is a long-acting amylin analogue that acts on central appetite pathways in the brain, helping to promote earlier and more sustained feelings of fullness.
By combining GLP-1 and amylin pathway activation, CagriSema is designed to support more comprehensive appetite control, reduce hunger intensity, and improve eating regulation under medical supervision. These effects develop progressively and are closely linked to dose titration, individual physiological response, and ongoing clinical monitoring.
As with all prescription-based weight loss injections, CagriSema is intended to be used within a structured, doctor-guided weight management programme. It is not designed for standalone or unsupervised use, and treatment response should be evaluated over time within an appropriate medical framework.
Through combined GLP-1 and amylin pathway effects, CagriSema enhances the body’s natural satiety signalling. This allows individuals to feel satisfied earlier during meals and remain fuller for longer periods, which plays an important role in reducing overeating and excessive portion sizes.
The degree of appetite suppression varies between individuals and depends on baseline appetite patterns, metabolic factors, and treatment tolerability. Satiety effects typically become more consistent as the body adapts during the initial phase of treatment.
By modulating hunger signals and food-related reward pathways, CagriSema may help reduce persistent hunger, frequent snacking, and food cravings. Rather than enforcing dietary restriction, individuals often experience improved control over eating behaviour and reduced preoccupation with food.
This supports more sustainable eating patterns when combined with medical guidance and regular follow-up.
In addition to appetite control, the combined actions of cagrilintide and semaglutide may influence overall energy balance by supporting reduced caloric intake and improved eating regulation. This contributes to gradual and sustained weight reduction when treatment is used appropriately under medical supervision.
Weight loss response remains individual and depends on adherence, dose tolerance, and ongoing clinical review. CagriSema does not replace medical care or long-term weight management strategies, and outcomes should always be assessed within a doctor-guided programme.
CagriSema is intended for use only within a medically supervised weight management programme and is not suitable for cosmetic or unsupervised weight loss. Careful patient selection is essential, as suitability depends on individual health status, appetite regulation patterns, prior weight management history, and overall medical profile.
A structured medical assessment helps determine whether a combination injectable therapy such as CagriSema may be appropriate, while also identifying individuals for whom alternative prescription weight loss treatments or non-injectable options may be safer or more suitable.
CagriSema may be considered for individuals who experience difficulty achieving or maintaining weight loss despite sustained efforts with conventional weight management approaches. This may include patients who struggle with appetite control, persistent hunger, reduced satiety, or repeated weight regain despite structured attempts at diet- and lifestyle-based interventions.
In such cases, a doctor-guided injectable treatment may help support appetite regulation as part of a broader, medically supervised weight management strategy rather than a short-term solution.
CagriSema is designed to be prescribed and monitored by a doctor as part of a structured medical weight loss programme. Individuals who prefer a clinically supervised approach may benefit from regular medical review, dose titration, and monitoring of treatment response and tolerability.
Doctor supervision ensures that treatment remains appropriate, well tolerated, and aligned with longer-term health goals, rather than focusing solely on short-term weight reduction.
Before considering CagriSema, a comprehensive medical evaluation is required. This includes reviewing medical history, current medications, prior response to weight loss treatments, weight-related health risks, and potential contraindications.
Not all individuals are suitable candidates for combination injectable weight loss therapies. Proper medical assessment helps ensure patient safety, appropriate treatment selection, and realistic expectations regarding benefits, limitations, and long-term management.
Safety is a core consideration when prescribing any injectable medication for medical weight management. As an investigational combination therapy, CagriSema should only be considered within a structured, doctor-guided programme that includes appropriate medical assessment, monitoring, and follow-up.
Because CagriSema acts on hormonal pathways involved in appetite regulation and satiety, individual tolerability varies. Ongoing medical supervision allows potential side effects to be anticipated, identified early, and managed appropriately throughout treatment.
As with other injectable weight loss medications that influence appetite-regulating hormones, some individuals may experience side effects, particularly during the initial phase of treatment or dose escalation. These may include gastrointestinal symptoms or changes in appetite as the body adapts.
Side effects are typically monitored closely by the prescribing doctor, and dose adjustments may be made to improve tolerability. Not all individuals experience side effects, and the severity and duration vary between patients.
CagriSema is intended to be introduced gradually through structured dose titration. This approach allows the body to adapt to treatment, helps reduce the likelihood of side effects, and supports more consistent appetite regulation over time.
Individual response to treatment differs based on physiological factors, baseline appetite patterns, and overall health profile. Regular follow-up ensures that dosing remains appropriate and aligned with treatment goals.
Doctor supervision is essential throughout treatment with CagriSema. Ongoing monitoring allows treatment response, side effects, and overall health parameters to be reviewed and addressed promptly.
Medical oversight also ensures that treatment remains suitable over time and that adjustments can be made if tolerability issues arise or if alternative weight management strategies become more appropriate. CagriSema should not be used without proper medical guidance or follow-up.
When considering CagriSema for medical weight management, it is important to understand both the potential weight loss outcomes observed in clinical research and the limitations that may influence individual results. As an investigational combination injectable therapy, CagriSema has been evaluated in large clinical studies involving adults with overweight or obesity, including individuals with and without metabolic conditions.
Clinical research has shown that combination therapies targeting both GLP-1 and amylin pathways may support meaningful weight reduction over time when used under medical supervision. However, expected weight loss outcomes vary significantly between individuals and should not be assumed to be uniform or guaranteed.
CagriSema is intended to support gradual and sustained weight reduction rather than rapid or short-term weight loss. Treatment response should be assessed over an extended period and within the context of a structured, doctor-guided programme.
Weight loss response with CagriSema varies widely between individuals. Factors influencing outcomes include baseline body weight, metabolic health, appetite regulation patterns, treatment tolerability, and adherence to dose titration schedules.
Some individuals may experience more pronounced appetite suppression and weight reduction, while others may achieve more modest results. A medical consultation is essential to establish realistic expectations based on individual health profiles.
Weight reduction with CagriSema typically occurs gradually rather than immediately. Appetite changes and improved eating control may develop progressively as the body adapts during dose escalation and early treatment phases.
Sustained weight reduction depends on continued medical monitoring, treatment adherence, and appropriate long-term planning. Short-term assessment alone does not accurately reflect treatment effectiveness.
While clinical studies provide valuable insights into potential outcomes, real-world results may differ from those observed in controlled research settings. Factors such as treatment adherence, lifestyle influences, tolerability, and access to ongoing medical support can affect real-world weight loss outcomes.
Like other prescription weight loss injections, CagriSema requires gradual dose titration and long-term medical follow-up. It is not intended as a standalone or temporary solution, and discontinuation of treatment may affect weight maintenance.
CagriSema does not replace comprehensive medical care or long-term weight management strategies. Outcomes should always be interpreted within the broader context of individual health goals, safety considerations, and doctor supervision.
While CagriSema represents an emerging combination injectable therapy for medical weight management, it is not currently available for routine clinical use in Singapore. Patients exploring medically supervised weight loss options may therefore consider other established prescription-based treatments that target appetite regulation through different hormonal pathways.
The choice of treatment should always be individualised and guided by a doctor, taking into account medical history, appetite patterns, tolerability, and long-term weight management goals.
Several prescription-based weight loss treatments act on the glucagon-like peptide-1 (GLP-1) pathway, which plays an important role in appetite suppression, satiety, and eating behaviour. These treatments are commonly used within structured, doctor-guided weight management programmes.
Ozempic is a once-weekly injectable GLP-1 receptor agonist prescribed under medical supervision to support appetite control and weight reduction.
https://edwinlimclinic.sg/ozempic-singapore/
Wegovy is a higher-dose GLP-1 injectable developed specifically for chronic weight management and used as part of a long-term, doctor-guided treatment programme.
https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
Some injectable weight loss medications act on more than one hormonal pathway involved in appetite regulation and metabolic signalling.
Mounjaro and Zepbound are once-weekly injectable treatments that target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) pathways. These may be considered for selected individuals following appropriate medical assessment.
https://edwinlimclinic.sg/zepbound-and-mounjaro-singapore-comprehensive-guide/
For individuals who prefer a non-injectable option, oral prescription-based weight loss treatments may be considered as part of a medically supervised programme.
Rybelsus is an oral form of semaglutide that acts on the GLP-1 pathway and may be suitable for selected patients who are unable or unwilling to use injectable therapies.
https://edwinlimclinic.sg/rybelsus-oral-weight-loss-medication-in-singapore/
Each medical weight loss treatment differs in mechanism of action, dosing structure, and tolerability profile. No single option is universally suitable for all individuals.
A comprehensive medical consultation allows the doctor to evaluate available alternatives to CagriSema and recommend a treatment approach aligned with individual health status, appetite regulation needs, and long-term safety considerations.
CagriSema is currently an investigational combination injectable therapy and has not yet been commercially launched for routine clinical use in Singapore. Availability depends on regulatory approval, clinical readiness, and local prescribing frameworks governing prescription-based weight loss medications.
At present, information on CagriSema in Singapore is primarily educational. Patients should be cautious of online claims regarding availability and rely on doctor-provided guidance rather than unofficial sources.
All prescription medications in Singapore must undergo regulatory review to assess safety, efficacy, and appropriate use before they can be offered in clinical practice. Until these processes are completed, CagriSema remains unavailable for routine prescription.
Regulatory timelines and approval status may evolve over time. Any future clinical use of CagriSema would be subject to regulatory clearance and doctor-led prescribing protocols.
The availability of new medical weight loss treatments often differs between countries due to variations in regulatory requirements, clinical guidelines, and healthcare frameworks. As a result, the timing of availability in Singapore may not mirror that of other regions.
Patients should avoid assuming local availability based on international news or clinical trial announcements.
While CagriSema is not currently available in Singapore, several established prescription-based medical weight loss treatments are already accessible under doctor supervision. These alternatives may be appropriate depending on individual medical profile and weight management goals.
A medical consultation allows patients to discuss current options, understand emerging therapies, and plan treatment based on what is clinically available and appropriate at the time. For personalised advice and up-to-date guidance, patients may contact the clinic directly:
https://edwinlimclinic.sg/contact-number/
Individuals interested in medically supervised weight loss can benefit from a personalised assessment by a licensed practitioner. A doctor will evaluate factors such as weight-history patterns, metabolic risk markers, medication suitability and potential contraindications before recommending an appropriate treatment plan. This ensures that any therapy selected aligns with clinical safety standards and long-term weight-management goals.
At Edwin Lim Medical Aesthetic Clinic, patients may consult Dr Edwin Lim to explore approved treatment options such as semaglutide, tirzepatide or oral GLP-1 medication, depending on their medical profile and treatment preferences. As new therapies like Orforglipron progress through clinical development, Dr Lim can also provide updates on future availability, emerging research data and how upcoming medications may fit into personalised treatment strategies once approved.
1. Individuals seeking professional guidance may schedule a consultation at:
Dr Edwin Lim
MBBS (Singapore), MRCS (Edinburgh), PgDip Practical Dermatology (Cardiff), MSc Practical Dermatology (Cardiff), Diploma in Aesthetic Medicine, (AAAM), Accredited by the Aesthetic Dermatology Educational Group (ADEG)
